Call for pharmacist access to the MBS for Chronic Disease Management
Pharmacists within general practice is a positive step forward, but the exclusion from MBS Team Care arrangements in CDM items makes no sense.
After a...
Treating hypertension – a new approach
Hypertension is the leading cause of cardiovascular disease, affecting 1.13 billion people worldwide, including six million adult Australians.
Research has indicated that a new pharmacological...
Resistance movement: Pharmacy’s fight against antimicrobial resistance
Antimicrobial resistance (AMR) has been ranked as serious a threat to society as terrorism. With millions of lives at risk, and trillions in GDP...
Re-thinking opioids
Pharmacists can minimise opioid harm by helping patients step down.
While opioids play an important role in the management of acute pain, their widespread use...
PSA’s projects make a bigger impact than ever before
The PSA released its 2025 Strategic Projects Impact Report last week, showcasing its leadership in advancing pharmacist practice.
Choosing wisely to achieve medicine safety
The quality use of medicines is vital to ensure a sustainable healthcare system and better health outcomes for consumers.
This was the dominant theme at...













